10x Genomics (TXG) Change in Acquisitions & Divestments (2022 - 2026)

10x Genomics has disclosed Change in Acquisitions & Divestments across 5 years of filings, most recently posting $25.0 million for Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $25.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $25.0 million (down 0.85% YoY), and the FY2024 annual result was $25.8 million, down 74.27% from the prior year.
• Change in Acquisitions & Divestments came in at $25.0 million for Q1 2026 at 10x Genomics, up from -$100.0 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $100.0 million in Q3 2025 to a low of -$100.0 million in Q4 2025.
• The 5-year median for Change in Acquisitions & Divestments is $21.9 million (2024), against an average of $13.3 million.
• Across the five-year window, Change in Acquisitions & Divestments jumped 1884.63% in 2023 and plunged 556.08% in 2025, its largest moves.
• 10x Genomics' Change in Acquisitions & Divestments stood at $7.7 million in 2022, then jumped by 286.99% to $29.9 million in 2023, then retreated by 26.57% to $21.9 million in 2024, then slumped by 556.08% to -$100.0 million in 2025, then jumped by 125.0% to $25.0 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $25.0 million (Q1 2026), -$100.0 million (Q4 2025), and $100.0 million (Q3 2025), per Business Quant data.